Significant increase of anticancer efficacy in vitro and in vivo of liposome entrapped ruthenium(II) polypyridyl complexes

Chen, Yi-Chuan; Li, Wenlong; Yang, Yan; Zhong, Ruitong; Hu, Huiyan; Chen, Jing; Liang, Lijuan; Liu, Yunjun

doi:10.1016/j.ejmech.2023.115541

Cited by 10 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…76−79 Interestingly, 4b-DCT-Lip had a better therapeutic effect on gastric tumor than the Ru(II)-Lip complex in vivo at a similar concentration. 79 Obviously, to improve the anticancer activity of metal complexes, we not only can rationally construct carriers of metal complexes but also can rationally combine them with another drug to trigger new anticancer mechanism(s) of metal complexes.…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, it has been a promising strategy for developing anticancer metal complexes based on Lip. For example, Liu et al used Lip to significantly improve the anticancer ability of Ru(II) and Ir(III) complexes with weak anticancer activity in vitro . − Interestingly, 4b -DCT-Lip had a better therapeutic effect on gastric tumor than the Ru(II)-Lip complex in vivo at a similar concentration . Obviously, to improve the anticancer activity of metal complexes, we not only can rationally construct carriers of metal complexes but also can rationally combine them with another drug to trigger new anticancer mechanism(s) of metal complexes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and Metastasis

Li,

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and Metastasis

Li,

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

“…Liposomes shared similar structural characteristics to biological membrane, hence it can be used as an effective carrier for enhanced lipophilicity of metal complexes. e. g., Chen et al [36] reported two biological inactive Ru III complexes:…”

Section: Ruthenium Complexesmentioning

confidence: 99%

Recent Progress in Ferroptosis Induced Tumor Cell Death by Anti‐tumor Metallic complexes

Zhou,

Zhao,

Tao

et al. 2024

Chemistry An Asian Journal

View full text Add to dashboard Cite

Metal complexes represented by platinum complexes play a very important role in cancer treatment due to their diverse chemical structures and anti‐tumor activities. Recently, ferroptosis has emerged as a newly occurring cell death form in the anti‐tumor process. It has been reported that metal complexes could inhibit the proliferation and metastasis of tumors and combat chemotherapy resistance by targeting ferroptosis. In this review, we briefly describe ferroptosis as a fundamental process for tumor suppression and triggering anti‐tumor immune responses. We summarize recent developments on metal complexes that induce ferroptosis. Finally, we outline the prospects for the application of metal complexes to the treatment of tumors based on ferroptosis and the associated problems that need to be solved, and discussed other potential research directions of metal complexes.

show abstract

“…[Ru(NO)(Et2NpyS4)]Br Chen et al ( 2023) [155] recently reported an interesting study on two polypyridyl Ru(II) complexes (48 and 49) and their cytotoxic activities in vitro toward A549 (lung adenocarcinoma), HepG2 (human hepatocellular carcinoma), SGC-7901 (gastric adenocarcinoma), HeLa (cervical cancer), BEL-7402 (hepatocellular carcinoma), and B16 (mouse melanoma) cells, as well as noncancer LO2 (hepatic fibroblast) cells, which were investigated using the MTT method. Unexpectedly, complexes 48 and 49 did not prevent these cancer cells' proliferation (IC50 > 200 µM, respectively, against all the cell lines).…”

Section: Structure Compound Cytotoxicity Studiesmentioning

confidence: 99%

“…IC 50 = 9.3 ± 0.3 µM (A549) IC 50= 17.4 ± 0.3 µM (HepG2) IC 50 = 3.4 ± 0.1 µM (SGC-7901) IC 50 = 14.8 ± 0.4 µM (HeLa) IC 50 = 5.9 ± 0.2 µM (Bel-7402) IC 50 = 7.2 ± 0.2 µM (B16)Chen et al (2023)[155] …”

unclassified

Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections

D’Amato,

Mariconda,

Iacopetta

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Poor responses to medical care and the failure of pharmacological treatment for many high-frequency diseases, such as cancer and viral infections, have been widely documented. In this context, numerous metal-based substances, including cisplatin, auranofin, various gold metallodrugs, and ruthenium complexes, are under study as possible anticancer and antiviral agents. The two Ru(III) and Ru(II) complexes, namely, BOLD-100 and RAPTA-C, are presently being studied in a clinical trial and preclinical studies evaluation, respectively, as anticancer agents. Interestingly, BOLD-100 has also recently demonstrated antiviral activity against SARS-CoV-2, which is the virus responsible for the COVID-19 pandemic. Over the last years, much effort has been dedicated to discovering new dual anticancer–antiviral agents. Ru-based complexes could be very suitable in this respect. Thus, this review focuses on the most recent studies regarding newly synthesized Ru(II) complexes for use as anticancer and/or antiviral agents.

show abstract

Significant increase of anticancer efficacy in vitro and in vivo of liposome entrapped ruthenium(II) polypyridyl complexes

Cited by 10 publications

References 62 publications

Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and Metastasis

Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and Metastasis

Recent Progress in Ferroptosis Induced Tumor Cell Death by Anti‐tumor Metallic complexes

Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections

Contact Info

Product

Resources

About